Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotech company, has been featured in a NetworkNewsWire editorial titled ‘Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers.’ The article sheds light on Calidi’s pioneering platform that employs engineered viruses to deliver genetic therapies directly to tumors, marking a significant advancement in the fight against cancer. This technology not only targets primary tumors but also metastatic ones, offering hope for patients with hard-to-treat cancers.
The editorial underscores the importance of Calidi’s work in the context of the increasing global cancer burden. By focusing on next-generation genetic medicines, Calidi is at the forefront of developing transformative treatment options that could change the landscape of oncology. The company’s research extends beyond cancer, with potential applications in autoimmune disorders, indicating a broader therapeutic impact.
Calidi’s approach utilizes proprietary stem cell-based platforms designed to enhance the efficacy and safety of oncolytic viruses. These platforms are part of Calidi’s clinical-stage off-the-shelf, universal cell-based delivery systems, which aim to protect, amplify, and potentiate oncolytic viruses. Additionally, the company is exploring preclinical off-the-shelf enveloped virotherapies targeting disseminated solid tumors, potentially addressing or even preventing metastatic disease.
The recognition by NetworkNewsWire highlights Calidi Biotherapeutics’ role in advancing genetic medicines and its commitment to addressing some of the most challenging diseases. For more information on Calidi’s innovative technologies and their implications for cancer treatment, visit https://ibn.fm/18sdm.
This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp
. The source URL for this press release is Calidi Biotherapeutics Inc. Featured in NetworkNewsWire Spotlight on Genetic Medicines for Cancer Treatment.
